Related references
Note: Only part of the references are listed.Frequency of CCR5 genotypes in HIV-infected patients in Roraima, Brazil
Andre de Lima Guerra Corado et al.
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES (2016)
Replicative Fitness Costs of Nonnucleoside Reverse Transcriptase Inhibitor Drug Resistance Mutations on HIV Subtype C
Kimberly L. Armstrong et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Deep Third Variable Sequencing for HIV Type 1 Tropism in Treatment-Naive Patients: A Reanalysis of the MERIT Trial of Maraviroc
Luke C. Swenson et al.
CLINICAL INFECTIOUS DISEASES (2011)
Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment
I. Abbate et al.
CLINICAL MICROBIOLOGY AND INFECTION (2011)
Theoretical Studies on the Interactions and Interferences of HIV-1 Glycoprotein gp120 and Its Coreceptor CCR5
Lin-tai Da et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2011)
Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease
Denis M. Tebit et al.
LANCET INFECTIOUS DISEASES (2011)
A combination of polymorphic mutations in V3 loop of HIV-1 gp120 can confer noncompetitive resistance to maraviroc
Yuzhe Yuan et al.
VIROLOGY (2011)
Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41
Cleo G. Anastasopoulou et al.
VIROLOGY (2011)
Features and development of Coot
P. Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)
Efficacy and Safety of Maraviroc Versus Efavirenz, Both With Zidovudine/Lamivudine: 96-Week Results From the MERIT Study
Juan Sierra-Madero et al.
HIV CLINICAL TRIALS (2010)
Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2
W. David Hardy et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
A Maraviroc-Resistant HIV-1 with Narrow Cross-Resistance to Other CCR5 Antagonists Depends on both N-Terminal and Extracellular Loop Domains of Drug-Bound CCR5
John C. Tilton et al.
JOURNAL OF VIROLOGY (2010)
HIV-1 Resistance to CCR5 Antagonists Associated with Highly Efficient Use of CCR5 and Altered Tropism on Primary CD4+ T Cells
Jennifer M. Pfaff et al.
JOURNAL OF VIROLOGY (2010)
Divergent Evolution in Reverse Transcriptase (RT) of HIV-1 Group O and M Lineages: Impact on Structure, Fitness, and Sensitivity to Nonnucleoside RT Inhibitors
Denis M. Tebit et al.
JOURNAL OF VIROLOGY (2010)
DNA Suspension Arrays: Silencing Discrete Artifacts for High-Sensitivity Applications
Matthew S. Lalonde et al.
PLOS ONE (2010)
HIV-1 Entry, Inhibitors, and Resistance
Michael A. Lobritz et al.
VIRUSES-BASEL (2010)
A novel yeast-based recombination method to clone and propagate diverse HIV-1 isolates
Dawn M. Dudley et al.
BIOTECHNIQUES (2009)
Adaptive Mutations in a Human Immunodeficiency Virus Type 1 Envelope Protein with a Truncated V3 Loop Restore Function by Improving Interactions with CD4
Caroline Agrawal-Gamse et al.
JOURNAL OF VIROLOGY (2009)
Selection of a Simian-Human Immunodeficiency Virus Strain Resistant to a Vaginal Microbicide in Macaques
Dawn M. Dudley et al.
JOURNAL OF VIROLOGY (2009)
Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities
Pavel Pugach et al.
VIROLOGY (2009)
Molecular architecture of native HIV-1 gp120 trimers
Jun Liu et al.
NATURE (2008)
Subgroup analyses of Maraviroc in previously treated R5 HIV-1 infection
Gerd Faetkenheuer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Maraviroc for previously treated patients with R5 HIV-1 infection
Roy M. Gulick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120
Robert A. Ogert et al.
VIROLOGY (2008)
Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists
Rama Kondru et al.
MOLECULAR PHARMACOLOGY (2008)
Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)
W. G. Nichols et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4
Chih-chin Huang et al.
SCIENCE (2007)
Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity
Michael A. Lobritz et al.
JOURNAL OF VIROLOGY (2007)
V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies
Meg M. Laakso et al.
PLOS PATHOGENS (2007)
Sensitive oligonucleotide Ligation assay for low-level detection of Nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies
Matthew S. Lalonde et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2007)
Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss
Cleo G. Anastassopoulou et al.
PLOS PATHOGENS (2007)
HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry
Pavel Pugach et al.
VIROLOGY (2007)
Viral fitness: relation to drug resistance mutations and mechanisms involved: nucleoside reverse transcriptase inhibitor mutations
Jan Weber et al.
CURRENT OPINION IN HIV AND AIDS (2007)
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry
Mike Westby et al.
JOURNAL OF VIROLOGY (2007)
Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism
Jeannette M. Whitcomb et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652
Masanori Baba et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-Infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir
M Westby et al.
JOURNAL OF VIROLOGY (2006)
Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy
S Palmer et al.
AIDS (2006)
Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine - HIVNET 012
SH Eshleman et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2005)
Generation and properties of a human immunodeficiency virus type I isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D)
AJ Marozsan et al.
VIROLOGY (2005)
Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching
C Pastore et al.
JOURNAL OF VIROLOGY (2004)
Relationships between infectious titer, capsid protein levels, and reverse transcriptase activities of diverse human immunodeficiency virus type 1 isolates
AJ Marozsan et al.
JOURNAL OF VIROLOGY (2004)
Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES
C Pastore et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors
B Labrosse et al.
JOURNAL OF VIROLOGY (2003)
Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C
SC Ball et al.
JOURNAL OF VIROLOGY (2003)
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics
JD Reeves et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use
A Trkola et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants
MD Iglesias-Ussel et al.
JOURNAL OF GENERAL VIROLOGY (2002)
Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES
AJ Marozsan et al.
JOURNAL OF VIROLOGY (2001)
A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5
T Dragic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs
VS Torre et al.
JOURNAL OF VIROLOGY (2000)
Share Paper
